COVID-19 Testing for the Essential Workforce
Learn about our efforts to test people on the front line and how you can help.
Research Studies
Open, pending, and completed studies
MiraKind has a pipeline of open and pending studies to identify new biomarkers of disease risk, as well as to help determine the best ways to protect the health of individuals with biomarkers of interest, such as the KRAS-variant.
Completed Studies
Hormones, the KRAS-variant and Breast Cancer Risk
This study has been completed and published, and was the first evidence that cancer risk for women with the KRAS-variant is uniquely impacted by hormonal exposures. Please see our follow-up study here.
Pending STUDIES
What is the Role of Hormone Replacement Therapy in Breast Cancer Risk?
Dating back to 2002, there have been several studies stating that hormone replacement therapy (HRT) increases the risk for breast cancer. HRT was vilified, and many women stopped using or never started using HRT. However, those findings do not apply to all women. For women with the KRAS-variant, HRT may be of a particular benefit.
The KRAS-variant and Pregnancy Associated Breast Cancer
This is a study to determine if women with the KRAS-variant are more likely to develop pregnancy associated breast cancer, which is breast cancer diagnosed within five years of being pregnant.
OPEN STUDIES
Open Study 1
This study will investigate the 'triggers' for an initial cancer diagnosis in KRAS-variant positive individuals.
Open Study 2
This study will investigate 'triggers' for a second cancer diagnosis in KRAS-variant individuals.
